Joshua T Kantrowitz1, Leslie Citrome. 1. Fellow, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA.
Abstract
BACKGROUND: Olanzapine is a second-generation antipsychotic approved for the treatment of schizophrenia, bipolar mania and associated agitation. OBJECTIVE: To assess the safety profile of olanzapine, including its propensity to be associated with weight gain, diabetes mellitus and dyslipidemias. METHODS: Review of English-language reports located through PubMed and information available on regulatory agency websites. RESULTS/ CONCLUSION: The use of olanzapine can pose a therapeutic dilemma in that on one hand, a number of large scale studies have found effectiveness advantages for olanzapine in comparison to other first-line second-generation medications. On the other hand, olanzapine is associated with substantial weight gain and the development of dyslipidemia. Regarding other important safety concerns, olanzapine has a favorable profile in terms of extra-pyramidal side effects and is also relatively prolactin-sparing. The effectiveness benefits may outweigh the risks, particularly in patients with low baseline risk for metabolic syndrome but monitoring for untoward metabolic effects crucial. Switch-or-stay and other intervention decisions need to be made early before substantial weight gain has occurred.
BACKGROUND:Olanzapine is a second-generation antipsychotic approved for the treatment of schizophrenia, bipolar mania and associated agitation. OBJECTIVE: To assess the safety profile of olanzapine, including its propensity to be associated with weight gain, diabetes mellitus and dyslipidemias. METHODS: Review of English-language reports located through PubMed and information available on regulatory agency websites. RESULTS/ CONCLUSION: The use of olanzapine can pose a therapeutic dilemma in that on one hand, a number of large scale studies have found effectiveness advantages for olanzapine in comparison to other first-line second-generation medications. On the other hand, olanzapine is associated with substantial weight gain and the development of dyslipidemia. Regarding other important safety concerns, olanzapine has a favorable profile in terms of extra-pyramidal side effects and is also relatively prolactin-sparing. The effectiveness benefits may outweigh the risks, particularly in patients with low baseline risk for metabolic syndrome but monitoring for untoward metabolic effects crucial. Switch-or-stay and other intervention decisions need to be made early before substantial weight gain has occurred.
Authors: Timothy L Ramsey; Herbert Y Meltzer; Guy N Brock; Bharat Mehrotra; Karu Jayathilake; William V Bobo; Mark D Brennan Journal: Pharmacogenomics Date: 2011-04 Impact factor: 2.533
Authors: Tatiana Dilla; Jörgen Möller; Paul O'Donohoe; María Álvarez; José A Sacristán; Michael Happich; Antje Tockhorn Journal: BMC Psychiatry Date: 2014-12-02 Impact factor: 3.630
Authors: Leslie Citrome; Joseph P McEvoy; Mark S Todtenkopf; David McDonnell; Peter J Weiden Journal: Neuropsychiatr Dis Treat Date: 2019-09-05 Impact factor: 2.570
Authors: Hai Bo Haber Xue; Li Liu; Hena Zhang; William Montgomery; Tamás Treuer Journal: Neuropsychiatr Dis Treat Date: 2014-05-16 Impact factor: 2.570